Chemistry:Rebecsinib
From HandWiki
Rebecsinib (17S-FD-895) is an experimental anticancer medication derived by modification of the natural product Pladienolide B, which acts as an inhibitor of splicing-mediated activation of the enzyme ADAR1, and is in development as a potential treatment for leukemia.[1][2][3][4][5]
See also
References
- ↑ "Remediating cancer via splicing modulation". Journal of Medicinal Chemistry 56 (17): 6573–6575. September 2013. doi:10.1021/jm401289z. PMID 23981063.
- ↑ "A Challenging Pie to Splice: Drugging the Spliceosome". Angewandte Chemie 56 (40): 12052–12063. September 2017. doi:10.1002/anie.201701065. PMID 28371109. Bibcode: 2017ACIE...5612052L.
- ↑ "Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells". Cell Reports. Medicine 4 (3). March 2023. doi:10.1016/j.xcrm.2023.100962. PMID 36889320.
- ↑ "Reversal of malignant ADAR1 splice isoform switching with Rebecsinib". Cell Stem Cell 30 (3): 250–263.e6. March 2023. doi:10.1016/j.stem.2023.01.008. PMID 36803553.
- ↑ "Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells". Biomedicines 11 (12): 3248. December 2023. doi:10.3390/biomedicines11123248. PMID 38137469.
 |  |
